Literature DB >> 411907

Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva.

J G Rogers, J P Dorst, W B Geho.   

Abstract

A boy with fibrodysplasia ossificans progressiva received nearly twice the usual therapeutic dose of disodium etidronate for 13 months in an attempt to prevent reossification following a second operation to correct severe torticollis. The operation was successful, but during therapy he developed weakness and distinctive bone lesions characterized by general osteopenia, widened physes, and unique radiolucent bands in the metaphyses. The osseous abnormalities were distinct from those of rickets and healed after withdrawal of the drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 411907     DOI: 10.1016/s0022-3476(77)80918-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Biphosphonates.

Authors:  J Allgrove
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

2.  Intravenous pamidronate in juvenile osteoporosis.

Authors:  N J Shaw; C M Boivin; N J Crabtree
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

3.  Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.

Authors:  Ryuichiro Yamamoto; Masaki Matsushita; Hiroshi Kitoh; Akio Masuda; Mikako Ito; Takenobu Katagiri; Tatsushi Kawai; Naoki Ishiguro; Kinji Ohno
Journal:  J Bone Miner Metab       Date:  2012-08-24       Impact factor: 2.626

4.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Authors:  Philip D Acott; Jaime A Wong; Bianca A Lang; John F S Crocker
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

Review 5.  Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?

Authors:  G Buyse; J Silberstein; N Goemans; P Casaer
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

6.  Chronic intoxication by ethane-1-hydroxy-1,1-diphosphonate (EHDP) in a child with myositis ossificans progressiva.

Authors:  U E Pazzaglia; G Beluffi; A Ravelli; G Zatti; A Martini
Journal:  Pediatr Radiol       Date:  1993

Review 7.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

8.  MYOSITIS OSSIFICANS PROGRESSIVA: CASE REPORT.

Authors:  Frederico Barra de Moraes; Alano Ribeiro de Queiroz Filho; Leonardo Jorge da Silva; Válney Luiz da Rocha; Nayara Portilho Araújo; Ernesto Quaresma Mendonça; Érica Paiva de Almeida
Journal:  Rev Bras Ortop       Date:  2015-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.